Skip to content

PharmaSynth AS

Registry code (registrikood) 11044101Public limited company (Aktsiaselts)VAT EE100940196Activity (EMTAK 21101): Põhifarmaatsiatoodete tootmineActive

Tartu linn, Tartu County · Financial data: annual reports up to 2025; tax data up to 2026 Q3

Revenue (2025)
€896k
▲ 52.8% vs 2024
Profit before tax (2025)
€236k
Employees, FTE (2025)
9
State taxes paid, last 4 quarters
€168k

Revenue, profit and employees, 2019–2025

€319k2019€444k2020€511k2021€476k2022€635k2023€587k2024€896k2025
YearRevenue (müügitulu)Operating profit (ärikasum)Net profitEquity (omakapital)Employees, FTE
2019€319,371€42,713€42,880€182,3648
2020€444,406€204,183€199,141€381,5057
2021€510,772€238,881€247,819€629,3247
2022€475,618€113,814€121,436€750,7607
2023€635,352€153,209€145,484€896,2447
2024€586,714€128,395€152,148€1,048,3928
2025€896,270€289,216€236,116€1,284,5089

Balance sheet summary

YearCashTotal assetsCurrent liabilitiesNon-current liabilitiesEquity
2019€157,471€239,082€45,479€11,239€182,364
2020€331,134€437,233€55,728€0€381,505
2021€503,502€679,080€49,756—€629,324
2022€540,736€833,351€82,591—€750,760
2023€658,180€940,779€44,535—€896,244
2024€743,028€1,123,717€75,325—€1,048,392
2025€678,862€1,368,917€84,409—€1,284,508

Calculated ratios

Net profit margin = net profit ÷ revenue. Equity ratio = equity ÷ total assets. Seedata sources & methodology for how each figure is derived.

Quarterly tax and turnover data (EMTA)

QuarterState taxes paidWage taxesTurnoverEmployees
2022 Q1€19,012€20,015€124,2297
2022 Q2€16,704€15,588€113,6688
2022 Q3€19,036€19,929€108,9328
2022 Q4€24,295€25,556€139,7068
2023 Q1€30,068€31,743€194,8118
2023 Q2€34,125€36,061€144,9988
2023 Q3€30,191€31,857€189,3208
2023 Q4€30,656€32,096€102,8278
2024 Q1€31,248€32,989€139,7078
2024 Q2€33,098€35,258€105,1098
2024 Q3€34,016€35,984€188,7749
2024 Q4€39,879€42,231€144,8889
2025 Q1€44,449€47,436€231,3729
2025 Q2€37,212€39,265€205,83610
2025 Q3€43,134€46,593€76,88111
2025 Q4€45,565€48,589€226,81511
2026 Q1€42,273€46,184€140,51010
2026 Q2€40,437€42,809€198,7869
2026 Q3€39,503€42,807€127,2578

Source: EMTA quarterly published data, as of 10 October 2026. Covers state taxes and wage taxes actually paid and turnover and employee counts as declared by the company, not the annual report figures above.

About this data

In the 2025 financial year (period 1 January 2025–31 December 2025), PharmaSynth AS reported revenue of €896,270.

The company closed the 2025 financial year with a net profit of €236,116.

Revenue increased by 52.8% from €586,714 in 2024 to €896,270 in 2025.

Revenue grew at a compound annual rate of 18.8% between 2019 and 2025.

Equity accounted for 93.8% of total assets of €1,368,917 at the end of the 2025 reporting period.

With 9 full-time-equivalent employees in 2025, revenue per employee was €99,586.

Across the 4 most recent quarters declared to EMTA, up to Q3 2026, PharmaSynth AS reported €693,368 in turnover.

EMTA recorded 8 employees for the quarter ending Q3 2026, compared with 9 full-time-equivalent employees in the 2025 annual report.

Browse

Source

Source: Estonian e-Business Register open data (Centre of Registers and Information Systems, RIK), licence CC BY-SA 4.0, modified; Estonian Tax and Customs Board (EMTA) quarterly data. Downloaded 2026-11-16. This is not an official register extract — see ariregister.rik.ee.

Company data on this site is available under CC BY-SA 4.0.

To request a correction or the removal of this page, use the contact form. Removal requests are handled within 30 days, no justification required.